Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art – part one
Submission date: 2016-05-24
Final revision date: 2016-06-19
Acceptance date: 2016-06-20
Online publication date: 2016-07-18
Publication date: 2016-06-30
Reumatologia 2016;54(3):122-127
KEYWORDS
TOPICS
SLE, Sjögren syndrome and APS - aetiology, pathogenesis, clinical features and treatmentScleroderma, myositis and related syndromes - aetiology, pathogenesis, clinical features and treatment
ABSTRACT
The majority of rheumatic diseases belong to the group of autoimmune diseases and are associated with autoantibody production. Their etiology is not fully understood. Certain medications and environmental factors may have an influence on the occurrence of rheumatic diseases. Establishing a cause-effect relationship between a certain factor and disease induction is not always simple. It is important to administer the drug continuously or monitor exposure to a given factor in the period preceding the onset of symptoms. The lack of previously diagnosed autoimmune disease, or finally the lack of symptoms within a few weeks/months after discontinuation of the drug/cessation of exposure, is also important. The most frequently mentioned rheumatic diseases caused by drugs and environmental factors include systemic lupus erythematosus, scleroderma, systemic vasculitis, polymyositis, dermatomyositis, and Sjögren’s syndrome. The objective of this study is to summarize current knowledge on rheumatic diseases induced by drugs and environmental factors.
REFERENCES (31)
1.
Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun 2014; 48-49: 66-72.
2.
Pretel M, Marquès L, Espańa A. Drug-induced lupus erythematosus. Actas Dermosifiliogr 2014; 105: 18-30.
3.
Lieberman MR, Liebman TN, Alapati U, Khachemoune A. TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis. Dermatol Online J 2014; 21(2). pii: 13030/qt18r2916d.
4.
Quaresma MV, Bernardes Filho F, Oliveira FB, et al. Anti-TNF-and hydralazine drug-induced lupus. An Bras Dermatol 2015; 90 (3 Suppl 1): 125-129.
5.
Bukhari M. Drug-induced rheumatic diseases: a review of published case reports from the last two years. Curr Opin Rheumatol 2012; 24: 182-186.
6.
Araújo-Fernández S, Ahijón-Lana M, Isenberg DA. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. Lupus 2014; 23: 545-553.
7.
Bernier MO, Mikaeloff Y, Hudson M, Suissa S. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum 2009; 61: 476-481.
8.
Bove R. Autoimmune diseases and reproductive aging. Clin Immunol 2013; 149: 251-264.
9.
Li RH, Gebbie AE, Wong RW, et al. The use of sex hormones in women with rheumatological diseases. Hong Kong Med J 2011; 17: 487-491.
10.
Marzano AV, Tavecchio S, Menicanti C, Crosti C. Drug-induced lupus erythematosus. G Ital Dermatol Venereol 2014; 149: 301-309.
11.
Harnett DT, Chandra-Sekhar HB, Hamilton SF. Drug-induced lupus erythematosus presenting with cardiac tamponade: a case report and literature review. Can J Cardiol 2014; 30: 247.e11-2.
12.
Stöllberger C, Krutisch G, Finsterer J, Wolf HM. Dabigatran-induced lupus temporarily preventing blood group determination. Blood Coagul Fibrinolysis 2014; 25: 625-627.
13.
D’Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett 2000; 112-113: 421-432.
14.
Sánchez-Guerrero J, Karlson EW, Colditz GA, et al. Hair dye use and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1996; 39: 657-662.
15.
Zandman-Goddard G, Solomon M, Rosman Z, et al. Environment and lupus-related diseases. Lupus 2012; 21: 241-250.
16.
Nelson P, Rylance P, Roden D, et al. Viruses as potential pathogenic agents in systemic lupus erythematosus. Lupus 2014; 23: 596-605.
17.
Gianchecchi E, Fierabracci A. Gene/environment interactions in the pathogenesis of autoimmunity: new insights on the role of Toll-like receptors. Autoimmun Rev 2015; 14: 971-983.
18.
Sharma SK, Handa R, Sood R, et al. Bleomycin-induced scleroderma. J Assoc Physicians India 2004; 52: 76-77.
19.
Rünger TM, Adami S, Benhamou CL, et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 2012; 66: e89-96.
20.
McCormic ZD, Khuder SS, Aryal BK, et al. Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health 2010; 83: 763-769.
21.
Al Aranji G, White D, Solanki K. Scleroderma renal crisis following silicone breast implant rupture: a case report and review of the literature. Clin Exp Rheumatol 2014; 32: 262-266.
22.
Wilson RH, McCormick WE, Tatum CF, et al. Occupational acro-osteolysis. J Am Med Assoc 1967; 201: 577-581.
23.
Ward AM, Udnoon S, Watkins J, et al. Immunological mechanisms in the pathogenesis of vinyl chloride disease. Br Med J 1976; 1: 936-938.
24.
Straniero NR, Furst DE. Environmentally-induced systemic sclerosis-like illness. Baillieres Clin Rheumatol 1989; 3: 63-79.
25.
Marie I, Gehanno JF, Bubenheim M, et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014; 13: 151-156.
26.
Marie I, Gehanno JF. Environmental risk factors of systemic sclerosis. Semin Immunopathol 2015; 37: 463-473.
27.
Yamakage A, Ishikawa H, Saito Y, Hattori A. Occupational scleroderma-like disorder occurring in men engaged in the polymerization of epoxy resins. Dermatologica 1980; 161: 33-44.
28.
Bovenzi M, Barbone F, Pisa FE, et al. Scleroderma and occupational exposure to hand-transmitted vibration. Int Arch Occup Environ Health 2001; 74: 579-582.
29.
Philen RM, Posada M. Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report. Semin Arthritis Rheum 1993; 23: 104-124.
30.
Mendoza FA, Purohit S, Kenyon L, Jimenez SA. Severe eosinophilic syndrome associated with the use of probiotic supplements: a new entity? Case Rep Rheumatol 2012; 2012: 934324.
31.
Ouwehand AC, Rijkers GT. Severe eosinophilic syndrome: highly unlikely associated with the use of probiotic supplements! Case Rep Rheumatol 2013; 2013: 769127.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
